Abstract
Current options for treatment of diseases with a presumed autoimmune etiology such as multiple sclerosis (MS) are far from satisfactory. Most treatments are associated with undesirable side effects due to toxicity and lack of immunological specificity. For these reasons, one of the primary goals in the development of immunotherapies has been to achieve selective inactivation of disease-inducing lymphocytes in the absence of general immunosuppression. It appears that the peripheral immune system can be divided into two compartments: one in which positive responses are initiated and another one where tolerance is induced (Mitchison 1998). Augmenting of tolerance by immunoregulation ranks prominently among the various approaches studied for the treatment of autoimmune disorders. Strategies in this direction include induction of specific immunological tolerance via anergizing, deletion, or suppression of autoreactive clones (Van Paris et al. 1998). The role of some of these mechanisms in maintaining peripheral tolerance in vivo is still very much a matter of debate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antel JP, Becher B, Owens T (1996) Immunotherapy for multiple sclerosis: from theory to practice. Nat Med 2: 1074–1075
Ben-Nun A, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line.-Eur J Immunol 11: 949–952
Ben-Nun A, Wekerle H, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292: 60–61
Ben-Yehuda A, Bar-Tana R, Livoff A, Ron N, Cohen IR, Naparstek, Y (1996) Lymph node cell vaccination against the lupus syndrome of MRL/lpr/lpr mice. Lupus 5: 323–326
Bourdette DN, Witham RH, Chou YK, Morrison WJ, Atherton J, Kenny C, Liefeld D, Hashim GA, Offner H, Vandenbark AA (1994) Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 152: 2510–2519
Bourdette DN, Chou YK, Witham RH, Buckner J, Kwon HJ, Nepom GT, Buenafe A, Cooper SA, Allegretta M, Hashim GA, Offner H, Vandenbark AA (1998) Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. J Innnunol 161: 1034–1044
Chou YK, Morrison WJ, Weinberg AD, Dedrick R, Witham R, Bourdette DN, Hashim GA, Offner H, Vandenbark AA (1994) Immunity to TCR peptides in multiple eclerosis. II. T cell recognition of Vbeta 5.2 and Vbeta 6.1 CDR2 peptides. J Immunol 152: 2520–2529
Cohen IR (1991) T cell vaccination in immunological disease. J Intern Med 230: 471–477
Desquenne-Clark L, Esch TR, Otvos L, Heber-Katz E (1991) T cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 88: 7219–7223
Elias D, Tikochinsky Y, Frankel G, Cohen IR (1999) Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide. Int Immunol 11: 957–966
Gaur A, Ruberti G, Haspel R, Mayer JP, Fathman CG (1993) Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. Science 259: 91–94
Heber-Katz E, Acha-Orbea H (1989) The V region hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today 10: 164–169
Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246: 668–670
Kumar V, Sercarz EE (1993) The involvement of T cell receptor peptide-specific regulatory CD-4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med 178: 909–916
Kumar V, Sercarz E (1998) Induction or protection from experimental autoim- mune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells. J Immunol 161: 6585–6591
Kumar V, Tabibiazar-Geysen HM, Sercarz EE (1995) Immunodominant framework region 3 peptide from TCR V beta 8 2 chain controls murine experimental autoimmune encephalomyelitis. J Immunol 154: 1941–1950
Kumar V, Stellrecht K, Sercarz EE (1996) Inactivation of T cell receptor-peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis ( EAE ). J Exp Med 184: 1609–1617
Kumar V, Aziz F, Sercarz EE, Miller A (1997) Regulatory T cells specific for the same framework 3 region of the Vbeta8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J Exp Med 185: 1725–1733
Lider O, Karin N, Shinitzky M, Cohen IR (1987) Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure. Proc Natl Acad Sci USA 84: 4577–4580
Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR (1988) Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239: 181–183
Mitchison NA (1998) Introduction. In: Bock GR, Goode JA (eds) Immunological tolerance. Novartis Foundation Symposium 215. Wiley, Chichester, pp 1–4
O’Garra A, Steinman L, Gijbels K (1997) CD4+ T-cell subsets in autoimmunity, Cuff Opin Immunol 9: 872–883
Saruhan-Direskeneli G, Weber F, Meinl E, Petter M, Diegerich G, Hinkkanen A, Epplen JT, Hohlfeld R, Wekerle H (1993) Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. Eur J Immunol 23: 530–536
Vandenbark AA, Hashim G, Offner H (1989) Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341: 541–544
Vandenbark AA, Chou YK, Witham RH, Mass M, Buenafe A, Liefeld D, Kavanagh D, Cooper S, Hashim GA, Offner H, Bourdette DN (1996a) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 2: 1109–1115
Vandenbark AA, Hashim GA, Offner H (1996b) T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 43: 391–402
Van Paris L, Perez VL, Abbas AK (1998) Mechanisms of peripheral T cell tolerance. In: Bock GR, Goode JA (eds) Immunological tolerance. Novartis Foundation Symposium 215. Wiley, Chichester, pp 5–13
Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, Mor-F, Cohen IR, Steinman L (1996) Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 2: 899–905
Zhang J, Vandevyer C, Stinissen P, Raus J (1995) In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. J Immunol 155: 5868–5877
Zipp F, Kerschensteiner M, Dornmair K, et al (1998) Diversity of the anti-Tcell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain 121: 1395–1407
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Brocke, S. (2000). T Cell Receptor Peptides for the Vaccination Therapy of Multiple Sclerosis. In: Walden, P., Sterry, W., Hennekes, H. (eds) Therapeutic Vaccination Strategies. Ernst Schering Research Foundation Workshop, vol 30. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04183-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-04183-3_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04185-7
Online ISBN: 978-3-662-04183-3
eBook Packages: Springer Book Archive